WO2001062294A1 - Medicaments preventifs ou therapeutiques contenant des inhibiteurs de chymase en tant que principe actif, pour traiter des dermatites - Google Patents
Medicaments preventifs ou therapeutiques contenant des inhibiteurs de chymase en tant que principe actif, pour traiter des dermatites Download PDFInfo
- Publication number
- WO2001062294A1 WO2001062294A1 PCT/JP2001/001323 JP0101323W WO0162294A1 WO 2001062294 A1 WO2001062294 A1 WO 2001062294A1 JP 0101323 W JP0101323 W JP 0101323W WO 0162294 A1 WO0162294 A1 WO 0162294A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- carbon atoms
- carboxylic acid
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a pharmaceutical use of a chymase inhibitor, and more particularly, to a preventive or therapeutic drug for dermatitis containing a chymase inhibitor as an active ingredient.
- the inflammatory response is caused by pathogens such as bacteria and viruses, trauma and foreign bodies, and immune cells such as granulocytes, monocytes and lymphocytes eliminate immune pathogens, dead tissues and foreign bodies. It is. Dermatitis is an acute or chronic inflammatory condition of the skin. In recent years, atopic dermatitis has been increasing remarkably and has become a major problem.
- Atopic dermatitis is a chronic disease with recurrent exacerbations and remissions, mainly in pruritic eczema, and often causes allergic diseases such as deprivation, allergic rhinitis and bronchial asthma in patients or their families. (A. predisposition or family history) is found (J. Allergy Clin. Immunol. 104, S123, 1999).
- the pathology of atopic dermatitis is diverse and its cause is still unknown, but it is mainly due to natural products such as dae, wool, feathers, bacteria and fungi, food such as eggs and milk, or chemicals. It is thought that various substances, such as fibers and synthetic products such as detergents, develop as antigens. It has also been pointed out that in atopic dermatitis, skin dysfunction due to dry skin (dry skin) plays an important role.
- a biphasic skin inflammatory response is observed, for example, when the same antigen is administered intradermally to animals sensitized with an antigen such as Ascaris extract (J. Immunol. 131, 1096, 1983).
- the skin reaction of the eye is called the immediate phase reaction and peaks at about 1 hour after exposure to the antigen, and the skin reaction of the second phase is called the delayed phase reaction and the maximum reaction occurs 8 to 24 hours later. (Biol. Pharm. Bu 11.18, 239, 1995).
- the first-phase response is considered to be a response elicited by IgE and mast cells, as it is suppressed by histamine receptor antagonists.
- the mechanism of the late-phase reaction is not always clear, it is characterized by the remarkable eosinophil infiltration in the skin (Int. Arch. Allergy Immunol. 113, 196). , 1997). Eosinophil infiltration in the skin is said to be a characteristic skin histology of patients with atopic dermatitis (J. Am. Acad. Dermatol. 24, 1101, 1991).
- eosinophil cationic protein ECP
- ECP eosinophil cationic protein
- Medicina 34, 220, 1997 the clinical symptoms of atopic dermatitis are very similar to those of contact dermatitis classified as type IV allergic reaction (Medicin a 34, 220, 1997). It has also been suggested that type IV allergic reactions may be involved in the pathogenesis.
- a hapten such as DN FB (Dinitrofluorobenzene) can induce a typical type IV allergic reaction called contact hypersensitivity. It is generally known that repeated application of such a hapten to the skin induces a type I allergic reaction in addition to a type IV allergic reaction (J. Invest Dermatol). 105, 74 9, 1995). For example, repeated hapten application increases blood IgE levels and shifts the response over time to a pattern similar to a type I allergic reaction. Furthermore, in such an animal model, not only the response to nopten, but also the skin thickening before the application of the hapten gradually increases, and a phenomenon that dermatitis becomes chronic is observed. Based on these results, dermatitis caused by repeated application of hapten has attracted attention as an animal model of atopic dermatitis (anitex 10, 23, 1998).
- NCZNga a mouse model of spontaneous atopic dermatitis
- SPF Session-Pathogen-Free
- mice such as BALBZ c mice
- this dermatitis does not occur when coexisting with NCN ga mice, and this dermatitis is considered to be specific to NC / N ga mice (Latest Medicine, 53, 2848, 1998).
- this mouse was bred in an SPF environment, no skin abnormalities were observed, and it is highly likely that some environmental factors are involved in the development of dermatitis in this mouse.
- contact dermatitis is induced in the early stage of sensitization.
- a histamine antagonist / antiallergic agent is currently used as a therapeutic agent for atopic dermatitis other than topical steroids. Histamine antagonists are effective in removing pruritus, but of course Nevertheless, it does not lead to eradication of this disease.
- antiallergic agents such as tranilast, ketotifen, oxatomide, and azelastine hydrochloride are ineffective against the pathogenesis of atopic dermatitis, or are almost unsatisfactory even if effective. . This is thought to be because these drugs have an inhibitory effect on type I allergic reactions, but have little effect on eosinophil function or type IV allergic reactions (Jap. J. Pharmacol. 63, 73, 1993, jap, J.
- chymase is one of the serine proteases widely present in tissues such as skin, heart, blood vessel wall, and intestinal tract, mainly as mast cell granule components (Mast Cell Proteases in Immunology and Biology; Caughey, GH, Ed; Marcel Dekker, Inc .: New York, 1995). Since ancient times, chymase acted on rat peritoneal mast cells to cause degranulation (J. Immunol. 136, 3812, 1986), and chymase inhibitors suppressed IgE-mediated degranulation of mast cells. (Biochem, Int. 10, 863, 1985), and it was pointed out that the involvement of chimase in the function of mast cells was pointed out.
- chymase inhibitor examples include a low-molecular-weight chymase inhibitor and a peptide-based inhibitor shown in a compendium (Protease Inhibitors; Barrett et ai., Jids; Elssevier Science BV: Amsterdam, 1996).
- Reported ⁇ _keto acid derivatives W093-25574, Proc. Natl. Acad. Sci. USA, 1995, 92, 6738), a, a-difluoro-j3-keto acid derivatives (Japanese Unexamined Patent Publication No. No.
- the present invention suppresses the development of the disease state of dermatitis exhibiting a biphasic inflammatory response such as atopic dermatitis and dermatitis caused by repeated exposure to antigens,
- the aim is to provide safe and preventive or therapeutic drugs without side effects to improve the quality of daily life.
- the present inventors have focused on that atopic dermatitis exhibits a biphasic inflammatory response, and that the late-phase response plays an important role in the pathological condition.
- the present invention was found to show an effect of improving biphasic skin inflammatory response in the delayed onset phase response and to be effective against dermatitis caused by repeated exposure to antigens. completed.
- a pharmaceutical composition for preventing or treating dermatitis exhibiting a biphasic inflammatory reaction comprising a chymase inhibitor as an active ingredient.
- an agent for improving a delayed phase reaction of dermatitis exhibiting a biphasic inflammatory reaction comprising a chymase inhibitor as an active ingredient.
- a preventive or therapeutic agent for dermatitis caused by repeated exposure to an antigen containing a chymase inhibitor as an active ingredient.
- a method for preventing or treating dermatitis exhibiting a biphasic inflammatory response comprising a chymase inhibitor in an amount for improving the late-onset reaction and a pharmacologically acceptable carrier.
- a pharmaceutical composition is provided BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a Darraf diagram showing the time course of skin reaction in the ascaris-induced mouse biphasic dermatitis model of Example 2.
- FIGS. 2A, 2B and 2C show the chymase inhibitor (FIG. 2A) and the control agents prednisolone (FIG. 2B) and difenhi in the ascaris-induced biphasic dermatitis model of Example 3.
- FIG. 2 is a graph showing the effect of a dramin (FIG. 2C).
- FIGS. 3A and 3B are graphs showing the time course of skin reaction when the cytokimase (FIG. 3A) or histamine (FIG. 3B) of Example 4 was intradermally administered to mice.
- FIGS. 4A and 4B are graphs showing the dose dependence of chymase in the skin reaction when the human chymase of Example 4 was administered intradermally to mice (FIG. Is the reaction after 16 hours).
- FIG. 5 is a graph showing the effect of heat treatment on the dermatitis-inducing effect of the human Kimmase of Example 5.
- FIGS. 6A to 6E are photographs showing histological analysis of dermatitis induced when the human cytokimase of Example 6 was administered intradermally.
- FIG. B is dermatitis induced by Ascaris extract (1 hour later)
- FIG. 6C is dermatitis induced by Ascaris extract (24 hours)
- FIG. 6D is 1 hour after chymase administration.
- FIG. 6E is a photograph 24 hours after chymase administration.
- FIG. 8A shows the invites of human polynuclear leukocytes (PMN) of Example 8.
- FIG. 4 is a graph showing the concentration dependence of the effect of human chymase on migration ability in ro.
- FIG. 8B is a graph showing the effect of a chymase inhibitor on the action of human chymase to promote human PMN migration.
- FIG. 9 is a graph showing the time course of increase in auricle thickening in the mouse dermatitis model repeatedly applied with hapten of Example 9.
- FIG. 10 is a graph showing changes in chymase-like activity of the auricle in the mouse dermatitis model repeatedly applied with hapten of Example 9.
- FIGS. 11A to 1ID show the effects of chymase inhibitors in a mouse dermatitis model repeatedly applied with the hapten of Example 10 (FIG. 11A is a control drug, prednisolone, FIG. 11D indicates the effects of compound 35, compound 34, and compound 18, respectively).
- FIG. 12 is a graph showing the effect of chymase inhibitors on eosinophil increase in the skin in the mouse dermatitis model repeatedly applied with the hapten of Example 11.
- FIG. 13 is a graph showing the effect of a chymase inhibitor on the increase of skin mast cells in the mouse dermatitis model repeatedly applied with the hapten of Example 12.
- FIG. 15 is a graph showing the time-dependent changes in skin thickness when the human cytokimase of Example 13 was frequently administered intradermally to mice.
- FIG. 16 is a graph showing the time course of the number of cutaneous eosinophils when the human cytokimase of Example 14 was frequently administered intradermally to mice.
- FIG. 17 is a graph showing the time-dependent change in the skin histamine content when the cytokimase of Example 15 was frequently administered intradermally to mice.
- FIGS. 18A and 18B show that the human chymase of Example 16 was applied to mouse skin. Representative photographs obtained by analyzing the expression of SCF when histologically administered by multiple administrations into the skin (Fig. 18A shows normal skin, and Fig. 18B shows chymase-administered skin).
- FIG. 19 is a graph showing the results of examining the effect of the cytokimase of Example 17 on SCF expression in human keratinocytes by invitro.
- FIG. 21 is a graph showing the effect of a chymase inhibitor on the histological findings of spontaneous dermatitis (NC / N g a) mice of Example 18.
- FIGS. 22A and 22A are graphs showing the effect of a chymase inhibitor on the number of skin mast cells in the spontaneous dermatitis (NCZNga) mouse of Example 18;
- FIG. Transcutaneous mast cells, Figure 22B shows the results of back skin mast cells.
- FIGS. 23A and 23B are graphs showing the effect of a chymase inhibitor on the number of cutaneous eosinophils in the spontaneous dermatitis (NC / N ga) mouse of Example 18; FIG. Eosinophils in the transcutaneous skin, Figure 23B shows the results for eosinophils in the back skin.
- Chymase inhibitors that can be used in the present invention can be selected as substances that can inhibit chymase activity by using methods that can be used by those skilled in the art. As a selection method, for example, the method of Example 1 described later can be used. Compounds obtained in this way include those that have been previously reported as chymase inhibitors. It has been reported as a low-molecular-weight chymase inhibitor and a peptide-type inhibitor, as shown in, for example, a book (Protease Inhibitors; Barrett et al., Eds; Elssevier Science BV: Amsterdam, 1996). Na-keto acid derivatives (W093-25574, Proc. Natl. Acad. Sci.
- JP-A-8-208654, JP-A-10-245384 phenol ester derivatives (JP-A-10-87567), cefm derivatives (JP-A-10-87493), isooxazole derivatives (JP-A-10-87493) 11-1479), imidazolidine derivatives (W096-04248), hydantoin derivatives (JP-A-9-31061), quinazoline derivatives (W097-11941), and the like are preferable.
- a chymase inhibitor the following formula (I):
- ring A represents an aryl ring
- R 2 and R 3 are the same or different, and are hydrogen, an optionally substituted lower alkyl group having 1 to 4 carbon atoms, a halogen atom, a hydroxyl group, a lower alkoxy group having 1 to 4 carbon atoms, an amino Group, optionally substituted lower alkylamino group having 1 to 4 carbon atoms, optionally substituted lower aralkylamino group having 7 to 10 carbon atoms, optionally substituted carbon atom with a carboxylic acid group
- R 1 and R 2 A condensed hetero ring which may be substituted with a carboxylic acid may be formed together with the zen ring, and the carbon atom on the condensed hetero ring forms a carbonyl group.
- R 3 is the same as above,
- aryl ring represented by ring A in the general formula (I) include a benzene ring and a naphthalene ring.
- Preferred examples of lower Ararukiruami amino group of a lower alkylamino amino group and a carboxylic acid carbon atoms which may be substituted with a group 7-1 2-carboxylic acid and 1 carbon atoms which may be substituted with group 4 indicated by R 1
- R 1 2-carboxylic acid and 1 carbon atoms which may be substituted with group 4 indicated by R 1
- groups 4 indicated by R 1 include methylamino, ethylamino, propylamino, butylamino, carboxymethylamino, carboxyethylamino, carboxypropylamino, and carboxybutylamino.
- Benzylamino group, phenethylamino group, phenylpropylamino group, phenylenobutylamino group, canolepoxybenzinoleamino group, canoleboxylphenethylamino group, carboxyphenylpropylamino group, carboxyphenylamino group, lipoxyphenyl A butylamino group and the like are exemplified.
- Ashiru of carboxylic acid Ashiru reduction have been amino group with a lower fatty acid is carbon atoms, which may have 1-4 optionally substituted with a group, a carboxylic acid group an aromatic ring carboxylic acid which may be substituted by represented by R 1
- Preferred examples of the amino group acylated with a heteroaromatic carboxylic acid which may be substituted with a substituted amino group and a carboxylic acid group include a formylamino group, an acetylamino group, and a propionylamino group.
- sulfonylated amino group with a lower Anoreka Nsuruhon acid R carbon atoms which may be substituted with a carboxylic acid group represented by 1 1-4, at Cal Pont acid group in the optionally substituted aromatic sulfonic acid
- Preferred examples of the amino group sulfonated with a heteroaromatic ring sulfonic acid which may be substituted with a sulfonylated amino group and a carboxylic acid group include a methansnorethonylamino group, Ethanesulfonylamino group, butanepansulfonylamino group, butanesulfonylamino group, benzenesulfonylamino group, naphthalenesulfoaluminoamino group, pyridinsulfonylamino group, pyrrolylsulfonylamino group, carboxime Tansulfo-noreaamino
- Preferred examples of the lower alkyl group having 1 to 4 carbon atoms and substituted with the carboxylic acid group represented by R 1 include an acetic acid group, a propionic acid group, a butyric acid group, and a valeric acid group.
- Preferred examples of the lower alkylene group having 2 to 4 carbon atoms substituted with the carboxylic acid group represented by R 1 include an acrylic acid group and a crotonic acid group.
- Preferred examples of the optionally substituted lower alkyl group having 1 to 4 carbon atoms represented by R 2 or R 3 include a methyl group, an ethyl group, an n-propyl group and an n-butyl group.
- Linear alkyl groups, and iso Branched alkyl groups such as propyl, sec-butyl and t-butyl are exemplified, and a preferable example of a substituent of a lower alkyl group having 1 to 4 carbon atoms is a carboxylic acid group.
- halogen atom such as fluorine, chlorine, etc., a lower alkoxy group having 1 to 4 carbon atoms, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group, a carboxyethylamino group and the like.
- Preferred examples of the halogen atom represented by R 2 or R 3 include fluorine, chlorine, bromine, and iodine.
- Preferred examples of the lower alkoxy group having 1 to 4 carbon atoms represented by R 2 or R 3 include straight-chain groups such as methoxy, ethoxy, n-propyloxy and n-butoxy. Examples include a chain alkyloxy group and a branched alkyloxy group such as an isopropyloxy group, a sec-butoxy group, and a t-butoxy group.
- Preferred examples of the substituent of the lower alkylamino group having 1 to 4 carbon atoms include a carboxylic acid group, a halogen atom such as fluorine and chlorine, and a lower alkoxy group having 1 to 4 carbon atoms.
- Preferred examples of the optionally substituted lower aralkylamino group having 7 to 12 carbon atoms represented by R 2 or R 3 include a benzylamino group, a phenethylamino group, a phenylpropylamino group, and a phenylbutylamino group.
- Preferred examples of the substituent of the aralkylamino group include a carboxylic acid group, a halogen atom such as fluorine and chlorine, and a lower alkoxy group having 1 to 4 carbon atoms.
- R 2 or: R 3 in Ashiru reduction has been ⁇ Mi amino group substituted in substituted lower fatty acid having 1 to 4 carbon atoms in the carboxylic acid group represented, carboxylic acid
- carboxylic acid Preferred examples of an amino group acylated with an aromatic carboxylic acid optionally substituted with a carboxylic acid group and an amino group acylated with a heteroaromatic ring carboxylic acid optionally substituted with a carboxylic acid group These include formylamino, acetylamino, propionylamino, petyrylamino, benzoylamino, naphthoylamino, pyridylcarponylamino, pyrrolecarbonylamino, carboxyacetylamino.
- Ring A is a benzene ring
- R 1 and R 2 form together with the benzene ring to be substituted, may be substituted with a carboxylic acid, and the carbon atoms on the ring form a carboxy group
- Optionally condensed heterocycle examples include a tetrahydroquinoline ring and a benzoxazine ring, and specific examples thereof include a tetrahydroquinoline, a benzoxazine, a quinoxaline, a benzodioxane, a carboxytetrahydroquinoline, and a carboxy.
- Benzoxazine, carboxyquinoxalin, carboxybenzodioxane and the like are exemplified.
- Preferred examples of the lower alkyl group having 1 to 4 carbon atoms represented by X include a linear alkyl group such as a methyl group, an ethyl group, an n-propyl group and an n-butyl group, and an isopropyl group; sec—A branched alkyl group such as a butyl group and a t-butyl group is exemplified.
- Preferred examples of the lower alkoxy group having 1 to 4 carbon atoms represented by X include linear alkyloxy groups such as methoxy group, ethoxy group, n-propyloxy group and n-butoxy group, and Examples thereof include branched alkyloxy groups such as a pyroxy group, sec-butoxy group, and t-butoxy group.
- Preferred examples of the halogen atom represented by X include fluorine, chlorine, bromine and iodine.
- pharmacologically acceptable salts include acid addition salts such as hydrochloride, methanesulfonate, trifluoroacetate, and nitrate, and sodium and potassium salts.
- metal salts are: Another representative example of a preferred chymase inhibitor is of the formula ( ⁇ ):
- ring B represents a benzene ring, a pyridine ring, a pyrrole ring, or a benzoyl ring
- m represents 0, 1 or 2
- Y is substituted with a hydroxyl group, a nitro group, a halogen atom, a halogen atom Represents a lower alkyl group having 1 to 4 carbon atoms which may be substituted, or a halogen atom; represents a lower alkoxy group having 1 to 4 carbon atoms or an aralkyloxy group having 7 to 12 carbon atoms which may be substituted, or Y is And forming a naphthalene ring or a quinoline ring together with the substituted benzene ring;
- R 5 and R 6 are the same or different and are a hydrogen atom, a halogen atom, a lower alkyl group having 1 to 4 carbon atoms which may be substituted by a halogen atom, a nitro group, a cyano group, a pyrazolyl group, a tetrazolyl group, A carbonyl group which may be esterified with a lower alkyl group having 1 to 4 carbon atoms or an aryl group, or a halogen atom, a morpholino group, a phenylbiperazinyl group and a lower alkyl group having 1 to 4 carbon atoms.
- R 5 and R 6 represent a group forming a naphthalene ring or a quinoline ring together with the benzene ring to be substituted
- Z is a hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms which may be substituted by a halogen atom, an alkenyl group having 2 to 5 carbon atoms, an optionally substituted aralkyl group, which may be substituted
- Aromatic heterocyclic alkyl group, lower alkyl group having 1 to 4 carbon atoms or carboxymethyl group which may be esterified with aryl group, primary or secondary or amidated with cyclic amamine Represents a substituted carbonylmethyl group, an optionally substituted arylcarbonylcarbonyl group, or an optionally substituted arylalkyloxymethyl group)
- Preferred examples of the halogen atom represented by Y in the general formula ( ⁇ ) examples thereof include fluorine, chlorine, bromine and iodine.
- Examples of the lower alkyl group of a lower alkyl group having 1 to 4 carbon atoms which may be substituted by a halogen atom represented by Y include a methyl group, an ethyl group, an n-propyl group and an n-butyl group.
- Examples thereof include a linear alkyl group such as a group, and a branched alkyl group such as an isopropyl group, a sec-butyl group and a t-butyl group, and may have 1 to 1 carbon atoms which may be substituted with a halogen atom.
- Examples of the halogen atom of the lower alkyl group 4 include fluorine, chlorine, bromine and iodine.
- Examples of the lower alkoxy group of a lower alkoxy group having 1 to 4 carbon atoms which may be replaced by a halogen atom represented by Y include a methoxy group, an ethoxy group, an n-propyloxy group and Examples are linear alkyloxy groups such as n-butoxy group, and branched alkyloxy groups such as isopropyloxy group, sec-butoxy group and t-butoxy group, which have 1 to 1 carbon atoms which may be substituted with a halogen atom.
- Examples of the halogen atom of the lower alkoxy group 4 include fluorine, chlorine, bromine and iodine.
- Examples of the aralkyloxy group having 7 to 12 carbon atoms represented by X include a benzyloxy group, a phenethyloxy group, a phenylpropyloxy group, a naphthylethyloxy group, and the like, and preferably a benzyloxy group.
- halogen atom represented by R 5 or R 6 fluorine, chlorine, bromine or iodine are exemplified.
- the lower alkyl group having 1 to 4 carbon atoms which may be substituted with a halogen atom represented by R 5 or R 6 include a methyl group, an ethyl group, an n-propyl group and an n- Examples thereof include a linear alkyl group such as a butyl group and a branched alkyl group such as an isopropyl group, a sec-butyl group and a t-butyl group, and a lower alkyl group having 1 to 4 carbon atoms which may be substituted with a halogen atom.
- halogen atoms in alkyl groups include fluorine and salts
- Examples include sulfur, bromine and iodine.
- a preferred example of the lower alkyl group having 1 to 4 carbon atoms represented by R 5 or R 6 or the lower alkyl group having 1 to 4 carbon atoms of the carboxyl group which may be esterified with an aryl group is methyl.
- Straight-chain alkyl groups such as a group, ethyl group, n-propyl group and n-butyl group, and branched alkyl groups such as an isopropyl group, sec -butyl group and t-butyl group. .
- Examples of the alkoxy group of the lower alkoxy group having 1 to 4 carbon atoms which may be substituted with one or more substituents selected from methoxy, ethoxy, n-propyloxy and n A straight-chain alkyloxy group such as a butoxy group, and a branched alkyloxy group such as an isopropyloxy group and sec-butoxy group and a t-butoxy group.
- Examples of the halogen atom as a substituent include: Examples include fluorine, chlorine, bromine and iodine, which may be esterified with a lower alkyl group having 1 to 4 carbon atoms or an aryl group as a substituent.
- Preferred examples of the lower alkyl group having 1 to 4 carbon atoms of the carboxy group include straight-chain alkyl groups such as methyl group, ethyl group, n-propyl group and n-butyl group, and isopropyl group; sec —A branched alkyl group such as a butyl group and a t-butyl group is exemplified.
- Examples of the lower alkyl group having 1 to 4 carbon atoms which may be substituted with a halogen atom represented by Z include a methyl group, an ethyl group, an n-propyl group and an n-butyl group. Examples thereof include a linear alkyl group such as a group, and a branched alkyl group such as an isopropyl group, a sec-butyl group and a t-butyl group, and may have 1 to 4 carbon atoms which may be substituted with a halogen atom.
- Examples of the halogen atom of the lower alkyl group Examples include nitrogen, chlorine, bromine and iodine.
- Examples of the alkenyl group having 2 to 5 carbon atoms represented by Z include an aryl group, a propenyl group, an isopropenyl group, a butyr group and the like.
- Examples of the aralkyl group of the optionally substituted aralkyl group represented by Z include an aralkyl group having 7 to 12 carbon atoms, preferably a benzyl group, a phenethyl group, a phenylpropyl group, and a naphthylethyl group. An example is shown.
- Examples of preferable substituents of the optionally substituted aralkyl group include a carboxyl group, a cyano group and a nitro group which may be esterified by a lower alkyl group having 1 to 4 carbon atoms or an aryl group.
- a guanidino group is exemplified.
- Examples of the lower alkyl group of a carboxyl group which may be esterified with a lower alkyl group having 1 to 4 carbon atoms or an aryl group include a methyl group, an ethyl group, an n-propyl group and an n-butyl group. And a branched alkyl group such as an isopropyl group, a sec-butyl group and a t-butyl group.
- Examples of the primary amine of the carbonyl group amidated with a primary amine are preferably a linear or carboxyl group such as methylamine, ethylamine, isopropylamine, carboxymethylamine and the like.
- Amines having a monocyclic or polycyclic aromatic hydrocarbon group such as optionally substituted lower alkylamine having 1 to 4 carbon atoms, aniline, naphthylamine, etc., aminoviridine, aminopyrrole, etc.
- an aromatic heterocyclic group examples of the carboxylic acid of the amino group which may be amidated with a carboxylic acid or an amino acid include aliphatic carboxylic acids such as piperic acid and succinic acid, preferably having 2 to 5 carbon atoms.
- Examples include carboxylic acids or aliphatic dicarboxylic acids, and examples of amino acids include L-aspartic acid, Examples thereof include amino acids in which a carboxyl group such as 1-O-t-butyl-N-t-butoxycarbonyl-1-L-aspartic acid may be esterified or an amino group may be amidated.
- Examples of the guanidino group which may be substituted with a lower alkoxycarbonyl group include a guanidino group, a 2,3-, bis-t-butoxycarbonyldanidino group and the like, preferably having 2 to 5 carbon atoms.
- a guanidino group which may be substituted with an alkoxycarbonyl group is exemplified.
- Examples of the aromatic heterocyclic alkyl group which may be substituted and represented by Z include a Cheeralkyl group such as a 2-phenylmethyl group, a 2-phenylphenylethyl group, and a 2-Bruch group.
- Furfurylalkyl groups such as rylmethyl group and 2-furfurylethyl group, 2-pyridylmethyl group, 3-pyridylmethyl group, 4-pyridylmethyl group, pyridylalkyl groups such as 4-pyridylethyl group, 5-pyrimidinylmethyl group, etc.
- Pyridinylalkyl group such as 2-pyrazinylmethyl group; pyrazinylalkyl group such as 3-pyridazinylmethyl group; and tetrazolinolenoleyl group such as 5-tetrazolinolemethyl group.
- Examples of preferred substituents of the optionally substituted heterocyclic alkyl group include a lower alkyl group having 1 to 4 carbon atoms such as a methyl group and an ethyl group, and a carbon atom such as a carboxylmethyl group and a carbonyloxyl group. Examples are the carboxyl lower alkyl groups of Formulas 1 to 4.
- a lower alkyl group of a carboxymethyl group which may be esterified with a lower alkyl group having 1 to 4 carbon atoms or an aryl group represented by Z
- Examples of such a group include straight-chain alkyl groups such as methyl, ethyl, n-propyl and n-butyl, and isopropyl, sec-butyl and t-butyl.
- a branched alkyl group is exemplified.
- Examples of the primary amine of a carbonylmethyl group amidated by a primary or secondary or cyclic amide represented by Z are preferably methylamine, ethylethylamine, and isopropylamine. Having a monocyclic saturated hydrocarbon group such as a lower alkylamine having 1 to 4 carbon atoms which may be substituted with a chain or a carboxyl group such as carboxylic acid or carboxymethylamine, or cyclohexylamine. , Aniline, benzylamine, naphthylamine, etc.
- aminoviridine having a monocyclic or polycyclic aromatic hydrocarbon group
- aminoviridine aminomethylviridine, aminovirol, aminovirimidine
- examples include an amido having an aromatic heterocyclic group such as aminoindole and amininoquinoline, and having the aromatic hydrocarbon group or the aromatic heterocyclic group.
- a propyloxyl group which may be esterified with a lower alkyl group having 1 to 4 carbon atoms such as a methyl group, an ethyl group, an isopropyl group, a t-butyl group, or an aryl group;
- ⁇ may be replaced by a carboxyl group which may be esterified by a lower alkyl group having 1 to 4 carbon atoms such as a methyl group, an ethyl group, an isopropyl group, a t-butyl group or an aryl group.
- a carboxyl group which may be esterified by a lower alkyl group having 1 to 4 carbon atoms such as a methyl group, an ethyl group, an isopropyl group, a t-butyl group or an aryl group.
- a propyloxyl group which may be esterified with a lower alkyl group having 1 to 4 carbon atoms such as a methyl group, an ethyl group, an isopropyl group, a t-butyl group or an aryl group;
- Piperazi- which may be N-substituted by a lower alkyl group having 1 to 4 carbon atoms such as a methyl group, an ethyl group, an isopropyl group, a t-butyl group or a carboxyl group esterified with an aryl group.
- a lower alkyl group having 1 to 4 carbon atoms such as a methyl group, an ethyl group, an isopropyl group, a t-butyl group or a carboxyl group esterified with an aryl group.
- Examples of the carboxylic acid of the amino group which may be amidated with the carboxylic acid or amino acid of the above d) include piperic acid and succinic acid, and preferably have 2 to 5 carbon atoms.
- Examples include aliphatic monocarboxylic acids or aliphatic dicarboxylic acids, and examples of aminoic acids include L-aspartic acid, a-O-t butynole N-t-butoxycanoleponinole L-aspartic acid, j3—O_t—butyl-N_t—butoxycarboyl L-aspartic acid, etc.
- Examples of the amino acid may be a carboxyl group which may be esterified or an amino group may be amidated.
- the nitrogen atom on the ring may be a lower alkyl group having 1 to 4 carbon atoms such as a methyl group or an ethyl group, or a carboxynormethyl group, a t-butyl acetate group or the like. May be substituted with an optionally esterified carboxyl lower alkyl group.
- the secondary amide of a carbonylmethyl group amidated by a primary or secondary or cyclic amide represented by Z include di-lower alkyl amides such as dimethylamine and getylamine. Are exemplified.
- Examples of the cyclic amine of the carbonyl group which has been amidated with a primary or secondary or cyclic amide represented by Z include pyrrolidine and piperidine.
- Examples of the arylcarbonylmethyl group of the optionally substituted arylcarbonylcarbonyl group represented by Z include phenylcarbonylmethyl group and naphthylcarbonylmethyl group, and preferred examples of the substituent are A halogen atom such as a hydroxyl group, a nitro group, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, a methyl group optionally substituted by a halogen atom, an ethyl group, an n-propyl group, an n-butyl group; Linear or branched lower alkyl group having 1 to 4 carbon atoms such as isopropyl group, sec-butyl group, t-butyl group, methoxy group, ethoxy group, n —Propoxy group, n—butoxy group, isopropoxy group, sec —A straight-chain or branched lower alkoxy group having 1 to 4 carbon atom
- Examples of the optionally substituted aralkyloxymethyl group represented by Z include benzyloxymethyl group, phenethyloxymethyl group, and naphthylethyloxy group.
- an aralkyloxymethyl group having 8 to 13 carbon atoms such as a methyl group is exemplified.
- Examples of preferred substituents include a hydroxyl group, a nitro group, fluorine, chlorine, bromine or iodine.
- a halogen atom such as iodine, a methyl group which may be substituted with a halogen atom, an ethyl group, an n-propyl group, an n-butyl group, an isopropyl group, a sec-butyl group, a t-butyl group, etc.
- Lower alkyl group having 1 to 4 carbon atoms in the chain or branch which may be substituted with halogen atom, methoxy group, ethoxy group, n-propyloxy group, n-butyl group
- Examples thereof include straight-chain or branched lower alkoxy groups having 1 to 4 carbon atoms, such as a ethoxy group, an isopropyloxy group, a sec-butoxy group and a t-butoxy group.
- Examples of pharmacologically acceptable salts include acid addition salts such as hydrochlorides and nitrates, and alkali metal salts such as sodium salts and potassium salts.
- the quinazoline derivative represented by the formula (I) of the present invention can be synthesized, for example, according to the following synthesis method (A) or (B). Synthesis method (A)
- R 1 represents R 1 which may be protected with a protecting group
- R 2 ′ represents R 2 which may be protected with a protecting group
- 3 ′ represents R 3 which may be protected by a protecting group
- R 1 , R 2 and R 3 are the same as defined above.
- a protecting group such as a t-butoxycarbonyl group, a benzyl group, an aryl group or a t-butyl group.
- X represents a hydroxyl group or an amino group, it may be protected with a protecting group such as a benzyloxy canoleponyl group, a t-butoxycarbonyl group, a benzyl group, an allyl group, or a t-butyl group, if necessary. Good.
- anthranilic acid derivative represented by the formula (1-2) used in this reaction a commercially available or known one or a compound that can be synthesized by a known method can be used.
- anthranilic acid, 4-chloroanthranilic acid, 4-methoxyanthranilic acid, 5-chloroanthranilic acid, 4-hydroxyanthranilic acid and the like can be used.
- the reaction for closing the quinazoline ring from the sulfonyl urea derivative represented by the formula (1-3) is performed in a non-protonic solvent, for example, an ether solvent such as tetrahydrofuran or dioxane, or a halogen such as methylene chloride.
- the reaction can be performed at a temperature of 50 ° C. to 50 ° C., preferably at 120 ° C. to room temperature, using a system solvent, dimethyl honolemamide, or the like.
- a normal dehydration condensing agent for example, CDI, dicyclohexyl carbodiimide (DCC), an analogous carbodiimide compound, a mixed acid anhydride and the like can be used.
- the deprotection reaction can be carried out by appropriately selecting a conventional method such as hydrolysis, reduction and oxidation with an acid or alkali.
- rings A, R 1 ′, R 2 ′, R 3 ′, R 4 and X are the same as defined above), and are hydrolyzed with an alkali or hydrolyzed to give the formula (1) — Derivation of the corresponding carboxylic acid shown in 3), followed by ring closure of the quinazoline ring in the same manner as in the synthesis method (A), and removal of the protecting groups of R 1 , R 2 , R 3 and X as necessary. It can be synthesized by protecting.
- R 1 , R 2 or R 3 when R 1 , R 2 or R 3 represents a group containing S, a hydroxyl group, an amino group or a carboxylic acid group, R 1 , R 2 or R 3 may be a benzyloxycarbonyl group as required. And t-butoxycarbonyl, benzyl, aryl, t-butyl and the like.
- X is a hydroxyl group When it represents an amino group or an amino group, it may be protected with a protecting group such as a benzyloxycarbonyl group, a t-butoxycarbonyl group, a benzyl group, an aryl group or a t-butyl group, as necessary.
- anthranilic acid derivative represented by the formula (1-5) used in this reaction a commercially available one, a known one, or a compound synthesized by a known method can be used. Mouth 2-Methyl N-phenoxycarboranlanthranilate, 4-Chloro-2-N-phenoxycarbonylanthra-ethylate, 4-Mouth-low 2-N-phenoxycanoleponinoleanthranolinoleic acid Benzinole, 5—Chloro-2-N-methyl phenoxycarpyllanthranilate, 5—Chloro2—N—Phenoxycarbonylane ethylate,
- the reaction of condensing with an anthranilic acid derivative to obtain a sulfonyl urea derivative represented by the formula (1-6) is a nonprotonic solvent such as Rahi Dorofuran, ether solvents such as Jiokisan, Ha androgenic solvents such as methylene chloride or with dimethyl formamidine de like, one 5 0
- the base used for the condensation reaction include strong organic bases such as DBU, inorganic bases such as potassium carbonate, sodium carbonate, potassium hydroxide, and sodium hydroxide, or hydrogenation. Metal bases such as sodium can be used. Wear.
- the above reaction can be carried out by protecting a functional group that does not participate in the reaction.
- the reaction is deprotected using a normal deprotection reaction such as chemical reduction.
- a normal deprotection reaction such as chemical reduction.
- the reaction can be performed using trifluoroacetic acid.
- the reaction can be performed using a palladium catalyst such as tetrakis (triphenylphosphine) palladium (0).
- R 1 is an amino group acylated with a lower fatty acid having 1 to 4 carbon atoms which may be substituted with a carboxylic acid group, or an aromatic ring carboxylic acid optionally substituted with a carboxylic acid group.
- R 1 represents an amino group, wherein the compound represents an amino group acylated with a heteroaromatic carboxylic acid which may be substituted with a functionalized amino group or carboxylic acid group.
- the compound can be obtained by acylation using the compound shown and a carboxylic acid, a carboxylic acid chloride, or a carboxylic acid anhydride by a usual method.
- R 1 may be substituted with a carboxylic acid group.
- Compounds showing an amino group sulfonylated with a sulfonic acid and an amino group sulfonated with a heteroaromatic sulfonic acid optionally substituted with a carboxylic acid group are represented by R in the formula (I). It can be obtained by sulfonylation in a usual manner using a compound in which 1 represents an amino group, sulfonic acid, and sulfonic acid chloride.
- the compound of the formula (II) of the present invention can be obtained in the same manner as described above, and more specifically, as described in International Publication WO097 / 11941.
- the obtained compound of the formula (I) or ( ⁇ ) can be purified by a usual purification method such as recrystallization or column chromatography. If necessary, the compound of the formula (I) Alternatively, the compound of (II) can be converted into a salt by reacting the compound with various acids or bases.
- Acids that can be used to convert the compounds of formula (I) or (II) into salts include inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and methanesulfonic acid; Organic acids such as benzenesulfonic acid, ⁇ -toluenesulfonic acid, trifluoroacetic acid, citric acid, lactic acid, maleic acid, fumaric acid, tartaric acid, acetic acid, adipic acid, palmitic acid and tannic acid .
- Examples of the base that can be used to convert the compound of the formula (I) or (II) into a salt include sodium hydroxide, lithium hydroxide, and hydroxylated water.
- the compounds of the formula (I) or (II) include those having an asymmetric center, and it is possible to isolate one optically active compound from the racemate by one or more methods. it can. For example,
- Etc. can be used.
- one or more of the compounds of the present invention may be formulated into a dosage form according to the administration method according to a conventional method.
- a conventional method can be used.
- dosage forms such as capsules, tablets, granules, fine granules, syrups, dry syrups, etc. are exemplified.
- suppositories for parenteral administration, in addition to injections, suppositories, vagina Suppositories such as suppositories, nasal administration agents such as sprays, and transdermal absorption agents such as ointments and transdermal absorption tapes are exemplified.
- the clinical dose of the compound of the present invention varies depending on symptoms, severity, age, presence or absence of complications, etc., and also varies depending on the preparation.
- the effective ingredient is usually 1 to 1 per adult. 1000 mg, in the case of parenteral administration, a dose of 1/10 to 1/2 of that in the case of oral administration may be administered. These dosages can be adjusted appropriately according to the patient's age, symptoms, and the like.
- the chymase inhibitor can be administered alone or as it is without being combined with other active ingredients.However, in consideration of applicable diseases, symptoms, complications, etc., other active ingredients are combined. It can also be administered as a pharmaceutical preparation. Also, it can be used in combination with these other active ingredients.
- the amount of the other active ingredients to be used is not particularly limited, but is determined in consideration of the minimum effect on its own, the occurrence of side effects, and the like.
- a preparation containing a chymase inhibitor alone as an active ingredient is appropriately selected by a physician according to the age and symptoms of the patient.
- the toxicity of the compound of the present invention is low, and acute toxicity value LD 5 24 hours after oral administration to 5-week-old male mice. Was over lg kg. This value is more than 50 times the expected clinical dose, and the safety of these compounds is considered to be high.
- Example 2 and 3 the usefulness of the chymase inhibitor is demonstrated by showing the inhibitory effect of the chymase inhibitor by using a mouse model of dermatitis exhibiting a biphasic inflammatory response. Further, in Examples 4 to 6, as evidence that further supports the involvement of chymase in dermatitis exhibiting a biphasic inflammatory response, inoculation of human chymase into the auricle of mice was carried out. It is proposed that dermatitis exhibiting a biphasic inflammatory reaction is induced, and the results of analyzing the mechanism of action of chymase in this biphasic dermatitis are shown in Examples 7 and 8.
- hapten-repetitive coating dermatitis was taken as a model of dermatitis caused by repeated exposure to antigen. Both demonstrate the effectiveness of chymase inhibitors by showing the effect of chymase inhibitors in this model. In patients with atopic dermatitis, etc., it is considered that mast cells repeatedly repeat degranulation by repeated exposure to allergens. The purpose of this study was to analyze the dermatitis caused by repeated inoculations of human chymomases into the auricle, with the aim of examining the effects on the skin of repeated degranulation reactions.
- Example 18 we show the effect of chymase administration on the expression of SCF, a major cytokine on mast cells, as one of the mechanisms of dermatitis induction.
- spontaneous dermatitis (NC / N ga) mice were used as the second model of dermatitis induced by repeated exposure to the antigen. 2 shows the effect of chymase inhibitors on lipase.
- the obtained crude product was dissolved in 50 ml of tetrahydrofuran (hereinafter abbreviated as THF), and under ice-cooling, 434 mg (2.68 mmol) of CDI was added, followed by stirring for 30 minutes.
- the reaction solution was diluted with ethyl acetate, washed with water and saturated saline, dried over anhydrous magnesium sulfate, and concentrated to obtain a crude product.
- the obtained aryl compound was dissolved in 100 ml of a formic acid-THF (1: 9) mixed solution, and 70 mg of triphenylphosphine was added.
- the reaction vessel was replaced with nitrogen while shielding the light from light, 700 mg of tetrax (triphenylphosphine) palladium (0) was added, and the mixture was stirred at room temperature for 1 hour while shielding the light.
- the solid obtained by concentrating the reaction solution under reduced pressure was washed with methylene chloride to obtain 1.47 g (yield 81%) of the title compound.
- Production Example 15 Synthesis of 4 — [(7-chloro-2,4 (1H, 3H) -quinazolindione-3-yl) sulfonyl] salicylic acid (Compound 15): 1.0 g (3.66 mmol) of 4-t-butoxycarbonyl 3-hydroxyhydroxysulfonamide and 1.12 g (3.66 mmol) of 4-t In the same manner as in Production Example 7, 1.79 g (yield: 100 o / o) of 2 -— [[(4-t—butoxycarbonyl_3—hydroxy) was obtained from N—methyloxycarbonylanthranilate in the same manner as in Production Example 7.
- Human heart chymase was purified according to the method of Urata et al. (J. Biol. Chem., 1990, 265 ⁇ 22348).
- DMSO dimethyl sulfoxide
- Table 1 shows the IC 5Q values of typical compounds.
- Ascaris-induced biphasic dermatitis was induced according to previously reported methods (Folia Pharmacol Jap 112, 221, 1998). That is, intraperitoneally of 8-week-old BALB / c mice (Charles River Japan, Inc.) were injected with R. scallis extract (800 / g / ml, Cosmopaio) and an aram saline solution (16 (mg / ml) was administered by injecting 0.5 ml of an equal volume mixture, and two weeks later, 10 ⁇ l of the alkaline extract (I mgZ ml) was injected into the right auricle. It was administered intradermally.
- Intradermal administration of the same antigen solution to the auricles of mice sensitized with the extract of Acacia induced biphasic dermatitis (Fig. 1). The first phase reaction peaked after 1 hour, and the second phase reaction peaked after 16 hours.
- test drugs were suspended in saline containing 0.5% hydroxypropyl cellulose and administered intraperitoneally 60 minutes before intradermal administration of the Ascaris extract.
- Intraperitoneal administration of a chymase inhibitor resulted in a 1-hour response (immediate-phase response) and a 16-hour response (slower response) for biphasic dermatitis induced by Ascaris extract.
- the phase response was suppressed in a dose-dependent manner, and a statistically significant difference was observed at a dose of 5 OmgZkg (Fig. 2A).
- the inhibition rate at 5 Omg / kg was about 41% for the immediate phase reaction and about 45% for the late phase reaction (both p ⁇ 0.01 and Dunnett's test).
- Prednisolone which is considered effective for atopic dermatitis, was almost ineffective against the immediate phase reaction, but strongly inhibited the late phase reaction at a dose of 30 mg / kg (suppression rate (67%) (Fig. 2B).
- diphenhydramine significantly inhibited the immediate-phase reaction (inhibition rate was 79%), but had little effect on the late-phase reaction (Fig. 2C).
- Recombinant human Kimmase was used for the test.
- Recombinant human kimchimase was obtained by expression and purification according to the previously reported serine protease production method (Biochem Biophys Acta 1350, 11, 1997). That is, first, cDNA (79-756) (J Biol Chem 266, 17173, 1991), which encodes mature human human kinase, is amplified by PCR, and the PCR product is amplified by human The region containing the signal sequence and the enterokinase cleavage site (23 amino acids) was cloned into the pDE vector.
- the constructed human chymase expression plasmid was transfected into CHO dhfr cells, and the transfected cells were selected by a previously reported method (Arch Biochem Biophys 307, 133, 1993).
- the fusion protein of human chymase and trypsin secreted into the culture supernatant of the obtained cells is concentrated using a HiTrap Heparin column (Amersnam Pharmacia Biotech ⁇ ) and then allowed to act on enterokinase (Invitrogen).
- a human mature chymase was produced.
- Human mature chymase was purified using a Heparin 5PW column (Tosoh Corp.).
- the purified chymase was assayed by SDS polyacrylamide gel electrophoresis and identified as a single band of 33-36 kDa.
- the enzyme activity was measured in 0.1 M Tris / HCl buffer (pH 8.0) using ImM Suc_Ala-Ala-Pro-Phe-MCA (Peptide Institute) as a substrate.
- the chymase activity could be identified by measuring the fluorescence intensity of the resulting MCA.
- histamine which is an inflammatory mediator of mast cells, was similarly intradermally administered, and its time-dependent change was compared with that of the case of administration of human kimkimase. Histamine (manufactured by Sigma-Aldrich) was dissolved in physiological saline (0.25 mg / ml) and used.
- FIG. 3A administration of human liver (2.0 ⁇ g / ear) to the auricle of a mouse gave a similar response to the allergic monodermatitis reaction shown in Example 2.
- a phasic edema response was elicited. That is, the first-phase skin reaction was induced immediately after chymase administration, and reached a peak 30 minutes to 1 hour later. The second phase skin reaction peaked after 6 hours and lasted at least 24 hours.
- histamine inoculation also induced a rapid edema reaction, but this skin reaction was completely abolished 20 hours after induction, in contrast to chymase inoculation (Fig. 3B). .
- dermatitis was induced by intradermal administration of human chymoxidase to mice, and that the change over time was similar to that of antigen-induced biphasic dermatitis, an acute model of atopic dermatitis.
- the involvement of chymase in biphasic dermatitis was shown.
- Example 5 In the case of dermatitis induced by a single administration of chymase, Involvement of mase activity
- Example 2 histopathological analysis of dermatitis induced by chymase was performed and compared with the biphasic dermatitis shown in Example 2.
- Each dermatitis was induced according to the method described in Example 2 and Example 4 (the dose of cytokinase was 2.0 ⁇ g / ear).
- the pinna at 1 hour and 24 hours in both models was fixed with formalin, and paraffin sections were prepared according to a conventional method. The sections were stained with hematoxylin and eosin, and then observed under a microscope and photographed.
- a pinna section of a normal BALBZc mouse was used as a negative control.
- Example 7 the mechanism of action of dermatitis induced by chymase was analyzed, and the role of chymase in biphasic dermatitis was examined.
- Example 7 Human chymase-induced dermatitis in mast cell-deficient mice Since chymase has been reported to induce degranulation in rat peritoneal mast cells (J. Immunol. 136, 3812, 1986). It was considered that dermatitis induced by chymase might have been caused by the release of inflammatory mediators from mast cells. Therefore, mutant mice without mast cells (Blood 52, 447-425 , 1978), the involvement of mast cells in chymase-induced dermatitis was examined. Mast cell-deficient (WBB6F1-W / W V ) mice and their control mice (WBB6F 1-+ / +) were both obtained from SLC Japan. Chymase dermatitis was induced by intradermal administration of human chymase (2.0 ⁇ g / ear), and the edema response at 1 hour and 16 hours was determined using the method described in Example 4. evaluated.
- Example 8 Migration action of human chymocyte on human polynuclear leukocytes
- Example 6 showed that marked leukocyte infiltration was observed in the second phase reaction of human chymocyte-induced dermatitis.
- PMN polynuclear leukocytes
- the migration ability of PMN was measured using a 48-hole chemotaxis champer (manufactured by Neuro Probe) according to the method described in the compendium (Biopharmaceutical Science Laboratory Course 12, 3, 15; Hirokawa Shoten). . That is, human chymase (200-800 nM) or fMLP
- human chymase is concentration dependent on human PMN Migratory promoting activity, and a statistically significant difference was observed at a concentration of 40 OnM or more. (P ⁇ 0.05, Dunnett's test). At a concentration of 200-400 nM, human lipase exhibited a migration promoting activity similar to that of 10 nM fMLP, indicating that the activity was about 1/30 that of fMLP. It was presumed to have. The activity of human chymase to promote human PMN migration was significantly suppressed by the chymase inhibitors Compound 18 and Compound 34 (FIG. 8B). These results suggest that chymase acts directly on polynuclear leukocytes and enhances their migratory ability, and indicates that the action involves enzyme activity.
- the pathology of biphasic dermatitis can be induced by externally administering chymase released from mast cells by antigen induction to the auricle of mice (Examples 4 to 6), indicating that chymase is biphasic. It has been shown to play an important role in skin reactions that exhibit Examples 7 and 8 also revealed the mechanism by which chymase participates in biphasic skin reactions. In addition, the inhibitory effect of chymase inhibitor was shown in ascaris-induced biphasic dermatitis, which is a biphasic inflammatory response. (Examples 2 and 3)
- DN FB dinitrofluorobenzene
- DNF B caused a transient skin reaction, which gradually increased with increasing number of applications (FIG. 9).
- DNFB increased the pinna thickness (basal value) before application, in addition to increasing the responsiveness to DNFB.
- the pinna thickness immediately before application was increased by about 240 ⁇ m compared to the pinna before the first application (Fig. 9).
- the control group to which only the solvent without DNFB was applied almost no auricle thickening was detected at any time.
- test substances three chymase inhibitor compounds (compound 18, compound 34, compound 35) and prednisolone (Nacalai Testa), a steroid agent, were used as control agents.
- test substance was suspended in saline (HPC / saline) containing the same 0.5% human Dorokishipuro pill cellulose as in Example 3, from hapten applied just before the start at 1 0 mg / kg or 5 0 mgZk g dose
- the drug was intraperitoneally administered once a day for 5 days every week, until the end of the experiment.
- a group to which DNFB was applied and HPC / saline was administered instead of the test substance was used as a control.
- Prednisolone inhibited dermatitis in this model in a dose-dependent manner Fig. 11A.
- chymase inhibitors also markedly suppressed the transient skin reaction caused by hapten application, especially after 4 weeks (3 weeks after the first hapten application) (Fig. 11B-D).
- compound 35 increases pinna thickness at 1, 4, 6, and 48 hours after 50-hour application of hapten at 4 to 6 weeks (3 weeks after the first hapten application) Significantly suppressed (p ⁇ 0.05, Dunnett's test).
- Example 11 Effect of chymase inhibitor on skin eosinophilia in mouse dermatitis model with repeated hapten application
- Example 10 the effect of chymase inhibitor on skin eosinophil infiltration was examined. That is, the pinna of each mouse was fixed with formalin 48 hours after the sixth hapten application, and a paraffin section was prepared according to a conventional method. The sections were stained using First Green (Fluka) (Current Protocol in Immunology, Wiley Interscience), which is known to specifically stain eosinophils. That is, the deparaffinized sections were fixed with 100% methanol for 1 minute, and then stained with Fast Green dissolved in 70% ethanol to a concentration of 0.2% for 30 minutes. Was done.
- First Green Fluorous a
- eosinophil measurement 10 fields were randomly selected under a microscope at a magnification of 400 times, and the number of cells per unit area was counted using a dalid attached to an eyepiece.
- Compounds 18 and 34 were used as chymase inhibitors, and administered by the method described in Example 10.
- the group to which the Acetone Z olypophil solution (3: 1) containing no DN FB was applied was used as a non-induced control group, and DN FB was applied, and 'HP CZ sa 1 ine instead of the test substance was used.
- the group to which was administered was used as a control for the chymase inhibitor-administered group.
- the number of eosinophils in the skin was significantly increased by repeated application of hapten (approximately 22 times that of the control group, 0.01%, Student's t-test).
- the increase in eosinophils was significantly suppressed in a dose-dependent manner of compound 18. That is, the inhibition rates at 10 mg / kg and 50 mg / kg were 37.1% and 60.5%, respectively.
- Compound 34 also responded to this eosinophilia Although no statistically significant difference was observed, a dose-dependent suppression tendency was observed. The above suggests that chymase inhibitors suppress skin eosinophilia in a hapten-repeated model.
- the effect of the chymase inhibitor on the increase of skin mast cells in the test of Example 10 was examined. 48 hours after the hapten was applied six times in the same manner as in Example 11, the pinna of each mouse was fixed with formalin, and paraffin sections were prepared according to a conventional method. The sections were stained for mast cells by the toluidine blue method, and the number of mast cells in each section of 10 visual fields was counted under a microscope (X400). The method of Kitagaki et al. (J. Invest. Dermatol. 105 , 749, 1995), and the skin mast cell density was measured. Compound 18 and compound 34 were used as chymase inhibitors, and administered by the method described in Example 10.
- the group to which the acetone / oliep oil solution (3: 1) containing DNFB was not applied was used as a non-induced control group, and the group to which DNFB was applied and HPC / saline was administered instead of the test substance was used as the chymase. It served as a control for the inhibitor-administered group.
- FIG. 13 skin mast cell density was significantly increased by hapten application (approximately 2.5 times that of the non-induced group).
- the results of administration of a force chymase inhibitor (compound 18 and compound 34) This increase in mast cell density was significantly suppressed for both compounds at both doses.
- the inhibition rate of Compound 18 was about 57% at 10 mg / kg, about 64% at 50 mg / kg, and the inhibition rate of Compound 34 was about 37% at 5 mg / kg. It was about 51% at 0 mg / kg.
- Figure 14 shows a typical micrograph.
- Fig. 14A shows the auricle of a non-elicited mouse, Fig.
- FIG. 14B shows the auricle of a mouse to which HPC / saline was administered to a mouse to which DNFB was applied (48 hours after applying DNFB 6 times), and Fig. 1. 4C administered compound 34 to mice coated with DNFB The auricles (48 hours after 6 applications of DNFB) of the mouse were shown. As described above, the chymase inhibitor was found to suppress the increase in the number of skin mast cells in the hapten repeated application model.
- human chymase was repeatedly administered intradermally to the pinna of mice.
- Human chymase was administered once a week according to the method described in Example 4 (2.0 ⁇ g / ear / shot).
- the pinna thickness after 4 hours and 48 hours was measured with a micrometer (Digimatic Indicator, manufactured by Mitsutoyo), and the increase relative to the pinna thickness before the first chymase administration was determined.
- a heat-treated chymase was prepared by the method described in Example 5, and the effects were simultaneously examined.
- Transdermal skin reactions were elicited by intradermal administration of human chymase to the mouse pinna.
- the responsiveness to chymase was almost the same between 1 and 3 doses, but was amplified by 4 and 5 doses (Fig. 15).
- No transient reaction was observed when heat-treated human chymase was treated, and no skin reaction was detected when the inactivated chymase was repeatedly administered (Fig. 15). This is due to the fact that the observed skin reaction is derived from the enzymatic activity of chymase, and the phenomenon of amplification of the skin reaction observed after 4-5 doses of chymase is due to the administration of the foreign protein to mice. It is not.
- Example 14 Effect of Frequent Administration of Human Chymomases on Eosinophil Count in Skin
- a change in skin eosinophil counts was examined by repeatedly intradermally administering human chymomases to the pinna of mice. Repeated administration of human chymomase to the mouse pinna was performed according to the method described in Example 13, and the number of skin eosinophils was measured in Example 11. This was performed by the method described in (1).
- As a control an auricular tissue to which saline was repeatedly administered was used.
- the number of eosinophils in the auricle 24 hours after the administration of 2.0 ⁇ g of human cytokimase was about 7 times greater than that in the saline-administered auricle. Increased 6-fold (p ⁇ 0.01, Student's t-te st).
- a total of four doses of human chymoxidase were administered at weekly intervals, and one week later, the number of skin eosinophils was similarly measured. The number of eosinophils further increased, and was about 21 times that of the saline-administered group. There was (p ⁇ 0.01, Student's t-test).
- chymase increased the number of skin eosinophils, and that the rate of increase might depend on the frequency of chymase exposure.
- Harmful Example 15 Effect of repeated administration of human cytokimase on the number of skin mast cells The change in the number of skin mast cells was repeatedly administered intradermally to human pinna.
- Repeated administration of human chymase was carried out according to the method described in Example 13, and one week after chymase administration, the skin mast cells were obtained by the method described in Example 12 or the method of measuring skin histamine content.
- the amount of histamine in the supernatant after 10 minutes was determined by using an ELISA kit (manufactured by the Institute of Medical Biology). As a control, an auricular tissue to which saline was repeatedly administered was used.
- SCF Stem Cell Factor
- a mast cell differentiation / proliferation factor aims to clarify the mechanism by which the number of mast cells in the skin increases upon administration of human chymase.
- Blood 90, 1345, 1997) was analyzed by immunohistochemical staining.
- human chymomases 2.0 g / ear were administered to the pinna of the mouse, and the pinna was searched at 1, 6, and 24 hours later.
- a frozen tissue section of 5 ⁇ m was prepared according to a standard method.
- a pinna section from a normal mouse was used as a control.
- Anti-mouse SCF goat IgG (manufactured by R & D Systems) was used as the primary antibody, and detection was performed using a PAP kit (manufactured by DAK0).
- PAP kit manufactured by DAK0
- normal goat IgG (manufactured by Vector laboratories) was used instead of the SCF antibody.
- nuclear staining was performed using methyl green (manufactured by Wako Pure Chemical Industries, Ltd.) in accordance with a conventional method (all staining methods, published by Yakuto Denki). In the auricle of normal mice, strong color development was observed around the stratum corneum of the epidermis (Fig. 18A).
- the normal antibody was used instead of the anti-SCF antibody as the primary antibody.
- SCF has two molecules of SCF 248 and SCF 22Q created by differences in splicing (Blood 90, 1345, 1997) .
- SCF 248 is Ichi ⁇ after being synthesized as a cell membrane protein is released into the free SCF and a connexion extracellular undergoing by connexion processed in some proteolytic enzymes You.
- SCF 22 ° functions only as a membrane protein because it lacks the site degraded by the enzyme (Blood 90, 1345, 1997). Longley et al. Found that SCF in healthy human skin was mainly expressed on the cell membrane of keratinocytes in the epidermis, but SCF expression on cells was not seen in dermatitis with multiplication of skin mast cells.
- Example 16 Longley et al. Also report that human chymase cleaves membrane-bound SCF and converts it to free SCF (Proc. Natl. Acad, Sci. US A, 94, 9017, 1997).
- the results obtained in Example 16 are completely novel findings that proved the data of Longley et al. Using inv ivo, and the results of Example 17 are the first data shown using human cells.
- the results of Examples 16 to 17 show that the skin mast cell number increased by the administration of chymase shown in Example 15 and the skin mast by the chymase inhibitor shown in Example 12 It can be said that this data explains the mechanism of the cell number increase suppression effect.
- the skin reaction is amplified as well as the number of administrations by repeatedly administering chymase, which is released from mast cells by antigen induction, to the mouse pinna from outside (Example 1). 3) From Chimase has been shown to play an important role in dermatitis caused by repeated exposure to antigens, and also shows that eosinophils and mast cells in the skin in repeated hapten-applied dermatitis. Chymase inhibitors suppress the increase (Examples 11 to 12).
- Chymase has been shown to regulate the number of eosinophils and mast cells, which play an important role in allergic reactions.
- chymase inhibitors ameliorate the pathology of dermatitis in a hapten repeatedly-applied dermatitis model, which is a model of dermatitis caused by repeated exposure to antigen.
- NC / Nga mice spontaneous dermatitis mice
- SPF Specific Patogen Free
- the evaluation was performed according to. First, 35 days after the start of administration, 1) rupture behavior, 2) edema, 3) redness and bleeding, The appearance of the skin was determined by scoring 0 to 2 for the 5 items of ⁇ hair loss, ulcer, and 5 dryness, and calculating the sum. After that, the auricle and back skin were fixed in formalin and embedded in paraffin. The auricle specimen was prepared using the hematoxylin-geosin method, the toluidine bunore method, or the congoles method (Stain Technol 56). 323, 1981), and the back skin was stained by the tollidine blue method or the congoled method and analyzed histologically.
- Auricular sections stained with hematoxylin and eosin were evaluated for histological changes in three stages from 0 to 3 for three items: (1) epidermal thickness, (2) dermal thickness, and (3) cell infiltration. The evaluation was made by expressing with. Specimens stained with toluidine blue and congoled were used for counting mast cells and eosinophils, respectively. Specifically, eosinophils on the back skin were counted in a microscope field of 400 ⁇ , and in all other cases, a total of 5 cells were counted in a field of view of 200 ⁇ and the total number was counted. Expressed.
- Figs. 20A and 20B at the start of the test (15 weeks of age), there was a difference between the control group and the chymase inhibitor (compound 18) -administered group in the scores of the dermatological symptoms.
- the dermatitis score was significantly reduced 35 days after administration of the chymase inhibitor compared to the control group (p ⁇ 0.05, Mann-Whitney test) (Fig. 20 OA).
- the pinna histological score was significantly reduced by administration of the chymase inhibitor (Fig. 21, p ⁇ 0.05, Mann-Whitney test).
- the number of mast cells in the pinna skin Fig. 22A
- the back skin Fig. 22B
- chymase inhibitors improve the appearance of the skin, histology of the skin, increase mast cells and The suppression of eosinophil infiltration demonstrated the usefulness of chymase inhibitors against dermatitis caused by repeated exposure to antigen.
- Compound 1 1000.0 g of Compound 1 was mixed with microcrystalline cellulose (22.5 g) and magnesium stearate (2.5 g), and the mixture was compressed using a single-shot tableting machine. Tablets 9 mg in diameter and weighing 250 mg were prepared containing mg of compound 1.
- Uitebsol H-15 (manufactured by Dynat Nobel) is heated and melted, and Compound 1 is added to the mixture at a concentration of 12.5 mg / ml, mixed uniformly, and then used for rectal suppositories. Each 2 ml of the mixture was poured into a mold and cooled to obtain a rectal suppository containing 25 mg of compound 1 in one preparation.
- a chymase inhibitor improves a biphasic skin inflammatory response or its late-onset response, thereby increasing the skin thickness of hapten repeatedly applied dermatitis, which is one of the animal disease models for atopic dermatitis.
- a biphasic inflammatory response such as atopic dermatitis, or dermatitis caused by repeated exposure to antigenscan effectively prevent and treat or treat the condition
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002368382A CA2368382A1 (en) | 2000-02-22 | 2001-02-22 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient |
US09/959,252 US7618977B2 (en) | 2000-02-22 | 2001-02-22 | Method of treating dermatitis comprising administering a chymase inhibitor |
KR1020017013473A KR20010109356A (ko) | 2000-02-22 | 2001-02-22 | 키마제 억제제를 유효성분으로 함유하는 피부염의 예방또는 치료제 |
HU0201282A HUP0201282A3 (en) | 2000-02-22 | 2001-02-22 | Preventive or therapeutic drugs for dermatitises containing quinazolindione derivative chymase inhibitors as the active ingredient |
AU34136/01A AU3413601A (en) | 2000-02-22 | 2001-02-22 | Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient |
EP01906226A EP1192950B1 (en) | 2000-02-22 | 2001-02-22 | Therapeutic drugs for dermatitis exhibiting a biphasic skin reaction containing chymase inhibitors as the active ingredient |
DE60121695T DE60121695T2 (de) | 2000-02-22 | 2001-02-22 | Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen |
US12/576,829 US20100029695A1 (en) | 2000-02-22 | 2009-10-09 | Method of treating dermatitis comprising administering a chymase inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-50504 | 2000-02-22 | ||
JP2000050504 | 2000-02-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/576,829 Continuation US20100029695A1 (en) | 2000-02-22 | 2009-10-09 | Method of treating dermatitis comprising administering a chymase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001062294A1 true WO2001062294A1 (fr) | 2001-08-30 |
Family
ID=18572276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/001323 WO2001062294A1 (fr) | 2000-02-22 | 2001-02-22 | Medicaments preventifs ou therapeutiques contenant des inhibiteurs de chymase en tant que principe actif, pour traiter des dermatites |
Country Status (11)
Country | Link |
---|---|
US (2) | US7618977B2 (ja) |
EP (1) | EP1192950B1 (ja) |
KR (1) | KR20010109356A (ja) |
CN (1) | CN1245979C (ja) |
AT (1) | ATE333897T1 (ja) |
AU (1) | AU3413601A (ja) |
CA (1) | CA2368382A1 (ja) |
DE (1) | DE60121695T2 (ja) |
ES (1) | ES2269347T3 (ja) |
HU (1) | HUP0201282A3 (ja) |
WO (1) | WO2001062294A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6500835B2 (en) | 2000-02-22 | 2002-12-31 | Suntory Limited | Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
US6677344B2 (en) | 2000-02-22 | 2004-01-13 | Daiichi Suntory Pharma Co., Ltd. | Chymase inhibitor for the treatment of eosinophilia |
JP2007511523A (ja) * | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | N−スルホニルジカルボキシイミド含有テザリング化合物 |
WO2007139230A1 (ja) | 2006-05-31 | 2007-12-06 | Asubio Pharma Co., Ltd. | 7員環化合物並びにその製造法および医薬用途 |
US7888348B2 (en) | 2004-12-02 | 2011-02-15 | Daiichi Sankyo Company, Limited | 7-membered ring compound and method of production and pharmaceutical application thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071307B2 (en) | 2005-04-04 | 2011-12-06 | Asubio Pharma Co., Ltd. | Method of detecting relative risk for the onset of atopic dermatitis by gene single nucleotide polymorphism analysis |
WO2015067651A1 (de) * | 2013-11-08 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | Substituierte uracile als chymase inhibitoren |
AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
US11639503B2 (en) * | 2017-11-30 | 2023-05-02 | Ribomic Inc. | Anti-chymase aptamer and use for same |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH059175A (ja) * | 1990-07-13 | 1993-01-19 | Yoshitomi Pharmaceut Ind Ltd | スチリル化合物およびその医薬用途 |
JPH05294930A (ja) * | 1992-04-21 | 1993-11-09 | Yoshitomi Pharmaceut Ind Ltd | スチリル化合物 |
EP0795548A1 (en) * | 1995-09-28 | 1997-09-17 | Suntory Limited | Quinazoline derivatives and use thereof |
JPH1087493A (ja) * | 1996-09-18 | 1998-04-07 | Shionogi & Co Ltd | セフェム系化合物を含有するキマーゼ阻害剤 |
JPH10101666A (ja) * | 1996-10-02 | 1998-04-21 | Shionogi & Co Ltd | 新規ベンゾオキサシクロトリデシン化合物およびそれを含有する医薬組成物 |
JPH10245384A (ja) * | 1997-03-05 | 1998-09-14 | Teijin Ltd | 新規トリアジンスルホン誘導体 |
WO2000051640A1 (fr) * | 1999-03-01 | 2000-09-08 | Welfide Corporation | Agents soulageant les demangeaisons et agents de potentialisation de cet effet de soulagement |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684654A (en) * | 1985-08-14 | 1987-08-04 | American Cyanamid Company | 3-heteroalkyl-2,4-quinzaolinediones |
IL79249A (en) * | 1986-06-26 | 1992-02-16 | Makhteshim Chem Works Ltd | Herbicidal compositions containing haloalkylthioquinazoline di(thi)ones and some new such compounds |
IE913473A1 (en) * | 1990-10-15 | 1992-04-22 | Fujisawa Pharmaceutical Co | Quinazoline derivatives and their preparation |
US5199279A (en) | 1991-08-13 | 1993-04-06 | Reynolds Martin M | Drum contact freezer system and method |
EP0644892A1 (en) | 1992-06-12 | 1995-03-29 | Pfizer Inc. | Inhibitors of angiotensin i chymase(s) including human heart chymase |
CZ291264B6 (cs) | 1993-05-12 | 2003-01-15 | E.I. Du Pont De Nemours And Company | Kondenzované bicyklické pyrimidinony, fungicidní prostředek a způsob potlačování padlí travního |
ES2155134T3 (es) * | 1994-07-29 | 2001-05-01 | Suntory Ltd | Derivados de imidazolidina y su utilizacion. |
KR100400639B1 (ko) | 1995-04-27 | 2003-12-31 | 미쯔비시 웰 파마 가부시키가이샤 | 복소환식아미드화합물및그의의약용도 |
US5596111A (en) | 1995-06-05 | 1997-01-21 | North Dakota State University | Method for preparation of carboxylic acids |
MXPA99002203A (es) | 1996-09-06 | 2003-09-15 | Nippon Kayaku Kk | Nuevos derivados de acetamida e inhibidores de proteasa. |
EP0940400A4 (en) | 1996-10-25 | 2002-10-02 | Mitsubishi Pharma Corp | NOVEL HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USE FOR MEDICINAL PURPOSES |
WO1999041277A1 (fr) | 1998-02-17 | 1999-08-19 | Nippon Kayaku Kabushiki Kaisha | Nouveau derive d'acetamide et son utilisation |
IL140862A (en) | 1998-07-15 | 2005-05-17 | Teijin Ltd | Thiobenzimidazole derivatives and pharmaceutical compositions containing the same |
KR20010089168A (ko) | 1998-08-21 | 2001-09-29 | 도리이 신이치로 | 퀴나졸린 유도체 및 이의 약제학적 용도 |
EP1142586B1 (en) | 1999-11-01 | 2007-04-25 | Daiichi Asubio Pharma Co., Ltd. | Use of chymase inhibitors against vascular lipid deposition |
DE60126199T2 (de) | 2000-02-22 | 2008-02-28 | Asubio Pharma Co., Ltd. | Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktive bestandteile |
AU3413401A (en) | 2000-02-22 | 2001-09-03 | Daiichi Asubio Pharma Co., Ltd. | Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
-
2001
- 2001-02-22 HU HU0201282A patent/HUP0201282A3/hu unknown
- 2001-02-22 EP EP01906226A patent/EP1192950B1/en not_active Expired - Lifetime
- 2001-02-22 CN CNB018007937A patent/CN1245979C/zh not_active Expired - Fee Related
- 2001-02-22 DE DE60121695T patent/DE60121695T2/de not_active Expired - Lifetime
- 2001-02-22 AU AU34136/01A patent/AU3413601A/en not_active Abandoned
- 2001-02-22 US US09/959,252 patent/US7618977B2/en not_active Expired - Fee Related
- 2001-02-22 KR KR1020017013473A patent/KR20010109356A/ko not_active Application Discontinuation
- 2001-02-22 ES ES01906226T patent/ES2269347T3/es not_active Expired - Lifetime
- 2001-02-22 AT AT01906226T patent/ATE333897T1/de not_active IP Right Cessation
- 2001-02-22 WO PCT/JP2001/001323 patent/WO2001062294A1/ja active IP Right Grant
- 2001-02-22 CA CA002368382A patent/CA2368382A1/en not_active Abandoned
-
2009
- 2009-10-09 US US12/576,829 patent/US20100029695A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH059175A (ja) * | 1990-07-13 | 1993-01-19 | Yoshitomi Pharmaceut Ind Ltd | スチリル化合物およびその医薬用途 |
JPH05294930A (ja) * | 1992-04-21 | 1993-11-09 | Yoshitomi Pharmaceut Ind Ltd | スチリル化合物 |
EP0795548A1 (en) * | 1995-09-28 | 1997-09-17 | Suntory Limited | Quinazoline derivatives and use thereof |
JPH1087493A (ja) * | 1996-09-18 | 1998-04-07 | Shionogi & Co Ltd | セフェム系化合物を含有するキマーゼ阻害剤 |
JPH10101666A (ja) * | 1996-10-02 | 1998-04-21 | Shionogi & Co Ltd | 新規ベンゾオキサシクロトリデシン化合物およびそれを含有する医薬組成物 |
JPH10245384A (ja) * | 1997-03-05 | 1998-09-14 | Teijin Ltd | 新規トリアジンスルホン誘導体 |
WO2000051640A1 (fr) * | 1999-03-01 | 2000-09-08 | Welfide Corporation | Agents soulageant les demangeaisons et agents de potentialisation de cet effet de soulagement |
Non-Patent Citations (2)
Title |
---|
DATABASE BIOSIS [online] IMADA TERUAKI: "Therapeutic potential of specific chymase inhibitor in atopic dermatitis", XP002938963, accession no. STN Database accession no. 2000:137872 * |
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 105, no. 1, PART 2, January 2000 (2000-01-01), pages S267, ABSTRACT 2000, XP002938964 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6500835B2 (en) | 2000-02-22 | 2002-12-31 | Suntory Limited | Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
US6677344B2 (en) | 2000-02-22 | 2004-01-13 | Daiichi Suntory Pharma Co., Ltd. | Chymase inhibitor for the treatment of eosinophilia |
JP2007511523A (ja) * | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | N−スルホニルジカルボキシイミド含有テザリング化合物 |
JP4913600B2 (ja) * | 2003-11-14 | 2012-04-11 | スリーエム イノベイティブ プロパティズ カンパニー | N−スルホニルジカルボキシイミド含有テザリング化合物 |
US7888348B2 (en) | 2004-12-02 | 2011-02-15 | Daiichi Sankyo Company, Limited | 7-membered ring compound and method of production and pharmaceutical application thereof |
EP2463268A1 (en) | 2004-12-02 | 2012-06-13 | Daiichi Sankyo Company, Limited | Aminomethyl-substituted aromatic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds |
US8507714B2 (en) | 2004-12-02 | 2013-08-13 | Daiichi Sankyo Company, Limited | 7-membered ring compound and method of production and pharmaceutical application thereof |
WO2007139230A1 (ja) | 2006-05-31 | 2007-12-06 | Asubio Pharma Co., Ltd. | 7員環化合物並びにその製造法および医薬用途 |
US8049006B2 (en) | 2006-05-31 | 2011-11-01 | Daiichi Sankyo Company, Limited | 7-membered ring compound and method of production and pharmaceutical application thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20010109356A (ko) | 2001-12-08 |
HUP0201282A3 (en) | 2003-02-28 |
DE60121695D1 (de) | 2006-09-07 |
US20020183339A1 (en) | 2002-12-05 |
US20100029695A1 (en) | 2010-02-04 |
ATE333897T1 (de) | 2006-08-15 |
US7618977B2 (en) | 2009-11-17 |
CN1245979C (zh) | 2006-03-22 |
HUP0201282A2 (hu) | 2002-12-28 |
AU3413601A (en) | 2001-09-03 |
EP1192950B1 (en) | 2006-07-26 |
CA2368382A1 (en) | 2001-08-30 |
CN1366460A (zh) | 2002-08-28 |
EP1192950A1 (en) | 2002-04-03 |
DE60121695T2 (de) | 2007-08-30 |
EP1192950A4 (en) | 2003-01-22 |
ES2269347T3 (es) | 2007-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10624882B2 (en) | Rho kinase inhibitors | |
US20100029695A1 (en) | Method of treating dermatitis comprising administering a chymase inhibitor | |
JP4775259B2 (ja) | アニリン誘導体 | |
JP2013500255A5 (ja) | ||
JP2013500255A (ja) | 自食作用の強力な小分子阻害剤、およびそれの使用方法 | |
TWI705815B (zh) | 用於治療補體相關疾病之組合物及治療方法 | |
AU6241399A (en) | Quinazoline derivatives as medicaments | |
US8883763B2 (en) | Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same | |
JPWO2010053120A1 (ja) | カルバメート化合物又はその塩 | |
CA2368366A1 (en) | Medicament for prevention or treatment of fibrosis having chymase inhibitor as effective ingredient | |
CN107296807B (zh) | Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用 | |
CN115286583B (zh) | 一种含二苯基氨基嘧啶类化合物、制备及其作为HDACs酶抑制剂的应用 | |
KR20010100004A (ko) | 키마제 억제 물질을 함유하여 이루어진 혈관 지질 침착방지제 | |
US6677344B2 (en) | Chymase inhibitor for the treatment of eosinophilia | |
TW201602086A (zh) | 作為抗癌藥物之芳基胺取代的喹喔啉 | |
AU2006201254A1 (en) | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | |
EP1403269A1 (en) | Remedial agent for viral infectious disease | |
WO2023119320A1 (en) | A preparation of quinazolinediones and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 01800793.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN HU JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
ENP | Entry into the national phase |
Ref document number: 2001 561357 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2368382 Country of ref document: CA Ref document number: 2368382 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 34136/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09959252 Country of ref document: US Ref document number: 1020017013473 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001906226 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017013473 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001906226 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001906226 Country of ref document: EP |